Purinyl Derivatives for Selective SK Channel Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with potassium channel activity, such as asthma and epilepsy, lack effective modulators for SK channels, which are crucial for regulating cellular functions and are implicated in various disorders.
Innovation Solution
Development of novel purinyl derivatives that selectively modulate SK channels, including SK1, SK2, and SK3 channels, by forming pharmaceutical compositions that can be administered to treat or alleviate associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for diseases associated with potassium channel activity are used, then existing therapeutic options are available, but effective modulators for SK channels are lacking
Solution Approach 1:
The patent applies local quality by designing purinyl derivatives with specific substituent patterns (R1, R2, R3, R4, R5, R6 positions) that target particular SK channel subtypes. Different substituent combinations (halo, alkyl, alkoxy, nitro, cyano groups) at specific positions on the purinyl core create compounds with selective affinity for SK1, SK2, or SK3 channels, enabling subtype-specific modulation while maintaining overall therapeutic efficacy.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the purinyl derivative structure (n=0,1,2,3; X=O,S, or NR'; different Y groups; various substituent types and positions) to optimize both therapeutic efficacy and channel selectivity. This structure-activity relationship approach allows tuning of compound properties to achieve desired biological effects with specific SK channel subtypes.
2Adaptability or versatility
If novel purinyl derivatives are developed to selectively modulate SK channels, then channel selectivity is improved, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent applies universality by creating a multi-functional purinyl derivative platform where a single core structure (purinyl with positions R1-R6) can generate multiple compounds with different selectivity profiles. The standardized core with variable substituent positions allows one molecular scaffold to target multiple SK channel subtypes or related potassium channels, reducing the need for entirely separate molecular designs for each target.
Solution Approach 2:
The patent uses segmentation by dividing the purinyl derivative into distinct functional regions: the core purinyl structure (positions 2,6,9), substitutable positions (R1-R6), and specific substituent types (halo, alkyl, alkoxy, nitro, cyano). This modular segmentation allows independent optimization of each region's contribution to channel binding, simplifying the design process despite the overall molecular complexity.
3Measurement precision
If purinyl derivatives with multiple substituent options are synthesized, then channel selectivity can be optimized, but the number of compounds to screen increases
Solution Approach 1:
The patent applies partial action by focusing screening efforts on specific substituent combinations that are most likely to yield selective SK channel modulators based on structure-activity relationship hypotheses. Rather than screening all possible substituent variations equally, the invention prioritizes certain R1-R6 configurations (such as specific halo or nitro substitutions at key positions) that show promise for achieving the desired selectivity profile with fewer compounds tested.
Data Source
AI summary
This invention relates to novel purinyl derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.